Available agents such as CDK4/6 inhibitors and oral SERDs, which have demonstrable clinical activity in advanced breast cancer, may overcome resistance to standard endocrine therapy that enables dormant tumors to emerge and spread. Here, CDK4 is linked to breast carcinoma.